Company intelligence / Profile preview

Nkure Therapeutics

Bangalore, Karnataka, Indiankure.com ↗

Ownership: Private
Development stage: Other

Overview

Nkure Therapeutics has developed a laboratory-scale NK cell immunotherapy platform, secured exclusive licenses to CAR and related technologies, and is co-developing CRISPR-edited NK cell therapies with CRISPR Therapeutics. The company is preclinical with no reported clinical trial results as of mid-2025.

Therapeutic areas: OncologyInfectious Diseases
Modalities: NK cell therapyCell therapyGene therapy
Industry: Biotech

Partnerships

CRISPR Therapeutics

Beyond the preview

Go deeper on Nkure Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nkure Therapeutics.